Literature DB >> 7518342

Steady state transcript levels of the type II hexokinase and type 1 glucose transporter in human tumor cell lines.

Y Shinohara1, K Yamamoto, K Kogure, J Ichihara, H Terada.   

Abstract

The steady state transcript levels of two hexokinase isozymes and type 1 glucose transporter in human tumor cell lines were analyzed. In HepG2 cells, both type II hexokinase and type 1 glucose transporter were highly expressed. However, in cell lines A431 and HeLa, in which the expression level of type 1 glucose transporter was lower than that in HepG2 cells, the amount of type II hexokinase transcript was almost negligible.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7518342     DOI： 10.1016/0304-3835(94)90142-2

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  18 in total

Review 1.  Targeting Cancer Metabolism and Current Anti-Cancer Drugs.

Authors:  Witchuda Sukjoi; Jarunya Ngamkham; Paul V Attwood; Sarawut Jitrapakdee
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy?

Authors:  Nissim Hay
Journal:  Nat Rev Cancer       Date:  2016-09-16       Impact factor: 60.716

Review 3.  How do glycolytic enzymes favour cancer cell proliferation by nonmetabolic functions?

Authors:  H Lincet; P Icard
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

4.  Linked Hexokinase and Glucose-6-Phosphatase Activities Reflect Grade of Ovarian Malignancy.

Authors:  Birgitte Brinkmann Olsen; Albert Gjedde; Mie Holm Vilstrup; Iben Birgit Gade Johnsen; Gudrun Neumann; Drew Avedis Torigian; Abass Alavi; Poul Flemming Høilund-Carlsen
Journal:  Mol Imaging Biol       Date:  2019-04       Impact factor: 3.488

Review 5.  18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer.

Authors:  D M Rose; D Delbeke; R D Beauchamp; W C Chapman; M P Sandler; K W Sharp; W O Richards; J K Wright; M E Frexes; C W Pinson; S D Leach
Journal:  Ann Surg       Date:  1999-05       Impact factor: 12.969

6.  Elevated Hexokinase II Expression Confers Acquired Resistance to 4-Hydroxytamoxifen in Breast Cancer Cells.

Authors:  Xiaochuan Liu; Weili Miao; Ming Huang; Lin Li; Xiaoxia Dai; Yinsheng Wang
Journal:  Mol Cell Proteomics       Date:  2019-09-13       Impact factor: 5.911

7.  Regulation of mammalian pyruvate dehydrogenase alpha subunit gene expression by glucose in HepG2 cells.

Authors:  J Tan; H S Yang; M S Patel
Journal:  Biochem J       Date:  1998-11-15       Impact factor: 3.857

8.  Local delivery of cancer-cell glycolytic inhibitors in high-grade glioma.

Authors:  Robert T Wicks; Javad Azadi; Antonella Mangraviti; Irma Zhang; Lee Hwang; Avadhut Joshi; Hansen Bow; Marianne Hutt-Cabezas; Kristin L Martin; Michelle A Rudek; Ming Zhao; Henry Brem; Betty M Tyler
Journal:  Neuro Oncol       Date:  2014-07-22       Impact factor: 12.300

9.  Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer.

Authors:  Qi Wang; Prashanth T Bhaskar; Krushna C Patra; Luke Miller; Zebin Wang; Will Wheaton; Navdeep Chandel; Markku Laakso; William J Muller; Eric L Allen; Abhishek K Jha; Gromoslaw A Smolen; Michelle F Clasquin; Brooks Robey; Nissim Hay
Journal:  Cancer Cell       Date:  2013-08-01       Impact factor: 31.743

10.  Integration of metabolomics, transcriptomics, and microRNA expression profiling reveals a miR-143-HK2-glucose network underlying zinc-deficiency-associated esophageal neoplasia.

Authors:  Louise Y Fong; Ruiyan Jing; Karl J Smalley; Cristian Taccioli; Johannes Fahrmann; Dinesh K Barupal; Hansjuerg Alder; John L Farber; Oliver Fiehn; Carlo M Croce
Journal:  Oncotarget       Date:  2017-06-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.